ArticleJournal of thoracic disease2024

Treatment rationale and protocol design: an investigator-initiated phase II study of combination treatment of nivolumab and TM5614, a PAI-1 inhibitor for previously treated patients with non-small cell lung cancer.

Takeshi Masuda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.